Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics
- 20 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 20 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01579357).
- 20 Apr 2012 Planned End Date changed from 28 Oct 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.